Zenas BioPharma, Inc.
ZBIO · XNASCIK 1953926fmd_1BB1D0GCG0HBXX7SJRGG5B5YKMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
Latest annual · FY2025
Millions- Total revenues
- 10
- Operating income
- (383)
- Net income
- (378)
- Free cash flow
- (172)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 10
- Operating income
- (103)
- Net income
- (109)
- Free cash flow
- (58)
Daily close · ZBIOIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions28.68 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Zenas BioPharma, Inc. (ZBIO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $10 million | $5 million | +100% | 10-K 2026-03-16 · proof |
| Operating income | -$383.1 million | -$163.9 million | 10-K 2026-03-16 · proof | |
| Net income | -$377.7 million | -$157 million | 10-K 2026-03-16 · proof | |
| Cash from operating activities | -$172.3 million | -$119.7 million | 10-K 2026-03-16 · proof | |
| Free cash flow | -$172.4 million | -$119.8 million | 10-K 2026-03-16 · proof | |
| Total assets | $383.6 million | $370 million | +3.7% | 10-K 2026-03-16 · proof |
| Total liabilities | $141.5 million | $57.5 million | +146% | 10-K 2026-03-16 · proof |
| Cash and cash equivalents | $110.6 million | $319.7 million | -65.4% | 10-K 2026-03-16 · proof |
- What was Zenas BioPharma, Inc. (ZBIO)'s revenue in fiscal 2025?
- Zenas BioPharma, Inc. (ZBIO) reported revenue of $10 million for fiscal 2025 (the year ended Dec 31, 2025), against $5 million the year before (+100%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Zenas BioPharma, Inc. (ZBIO)'s operating income in fiscal 2025?
- Zenas BioPharma, Inc. (ZBIO) reported operating income of -$383.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$163.9 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Zenas BioPharma, Inc. (ZBIO)'s net income in fiscal 2025?
- Zenas BioPharma, Inc. (ZBIO) reported net income of -$377.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$157 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Zenas BioPharma, Inc. (ZBIO)'s cash from operating activities in fiscal 2025?
- Zenas BioPharma, Inc. (ZBIO) reported cash from operating activities of -$172.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$119.7 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Zenas BioPharma, Inc. (ZBIO)'s free cash flow in fiscal 2025?
- Zenas BioPharma, Inc. (ZBIO) reported free cash flow of -$172.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$119.8 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Zenas BioPharma, Inc. (ZBIO)'s total assets?
- As of Dec 31, 2025, Zenas BioPharma, Inc. (ZBIO) reported total assets of $383.6 million, against $370 million a year earlier (+3.7%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Zenas BioPharma, Inc. (ZBIO)'s total liabilities?
- As of Dec 31, 2025, Zenas BioPharma, Inc. (ZBIO) reported total liabilities of $141.5 million, against $57.5 million a year earlier (+146%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Zenas BioPharma, Inc. (ZBIO)'s cash and cash equivalents?
- As of Dec 31, 2025, Zenas BioPharma, Inc. (ZBIO) reported cash and cash equivalents of $110.6 million, against $319.7 million a year earlier (-65.4%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ZBIO&period_type=annual&limit=5"Information only, not investment advice.